Elevation of neural injury markers in patients with neurologic sequelae after hospitalization for SARS-CoV-2 infection.
Elevation of neural injury markers in patients with neurologic sequelae after hospitalization for SARS-CoV-2 infection.
复制标题
DOI：
10.1016/j.isci.2022.104833
复制
发表时间：
2022-08-19
期刊：
影响因子：
5.8
通讯作者：
Das, Saumya
中科院分区：
文献类型：
--
作者：
Spanos, Michail;Shachar, Sigal;Sweeney, Thadryan;Lehmann, Immo;Gokulnath, Priyanka;Li, Guoping;Sigal, George B.;Nagaraj, Rajini;Bathala, Pradeepthi;Rana, Farhan;Shah, Ravi V.;Routenberg, David A.;Das, Saumya
Patients with SARS-CoV-2 infection (COVID-19) risk developing long-term neurologic symptoms after infection. Here, we identify biomarkers associated with neurologic sequelae one year after hospitalization for SARS-CoV-2 infection. SARS-CoV-2-positive patients were followed using post-SARS-CoV-2 online questionnaires and virtual visits. Hospitalized adults from the pre-SARS-CoV-2 era served as historical controls. 40% of hospitalized patients develop neurological sequelae in the year after recovery from acute COVID-19 infection. Age, disease severity, and COVID-19 infection itself was associated with additional risk for neurological sequelae in our cohorts. Glial fibrillary astrocytic protein (GFAP) and neurofilament light chain (NF-L) were significantly elevated in SARS-CoV-2 infection. After adjusting for age, sex, and disease severity, GFAP and NF-L remained significantly associated with longer term neurological symptoms in patients with SARS-CoV-2 infection. GFAP and NF-L warrant exploration as biomarkers for long-term neurologic complications after SARS-CoV-2 infection. 40% of hospitalized patients with COVID-19 developed neurological sequelae after recovery Age, disease severity, and COVID-19 infection were associated with neurological sequelae GFAP and NF-L were significantly elevated in SARS-CoV-2 infection compared to controls GFAP and NF-L were elevated in patients with long-term neurological symptoms Immunology; Neuroscience
登录
查看更多内容
影响因子：
3.4
作者：
Clarke GJB;Skandsen T;Zetterberg H;Einarsen CE;Feyling C;Follestad T;Vik A;Blennow K;Håberg AK
通讯作者：
Håberg AK
DOI：
10.1016/j.clinph.2021.03.016
发表时间：
2021-07
期刊：
Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology
影响因子：
--
作者：
Frithiof R;Rostami E;Kumlien E;Virhammar J;Fällmar D;Hultström M;Lipcsey M;Ashton N;Blennow K;Zetterberg H;Punga AR
通讯作者：
Punga AR
DOI：
10.1016/s1474-4422(20)30308-2
发表时间：
2020-11
期刊：
The Lancet. Neurology
影响因子：
--
作者：
Matschke J;Lütgehetmann M;Hagel C;Sperhake JP;Schröder AS;Edler C;Mushumba H;Fitzek A;Allweiss L;Dandri M;Dottermusch M;Heinemann A;Pfefferle S;Schwabenland M;Sumner Magruder D;Bonn S;Prinz M;Gerloff C;Püschel K;Krasemann S;Aepfelbacher M;Glatzel M
通讯作者：
Glatzel M
影响因子：
6.8
作者：
Chatterjee P;Pedrini S;Stoops E;Goozee K;Villemagne VL;Asih PR;Verberk IMW;Dave P;Taddei K;Sohrabi HR;Zetterberg H;Blennow K;Teunissen CE;Vanderstichele HM;Martins RN
通讯作者：
Martins RN
影响因子：
168.9
作者：
Huang, Chaolin;Wang, Yeming;Cao, Bin
通讯作者：
Cao, Bin